Cargando…

1252. In Vitro Activity of Cefiderocol Against Metallo-β-Lactamase-Producing Gram-Negative Bacteria Collected in North America and Europe Between 2014 and 2017: SIDERO-WT-2014–2016 Studies

BACKGROUND: Metallo-β-lactamases (MBLs; eg, NDM, VIM, and IMP) can inactivate most commonly-used β-lactam antibiotics, including carbapenems. Infections caused by MBL producers are difficult to treat due to their resistance to many antibiotics. Cefiderocol (CFDC) is a siderophore cephalosporin antib...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takemura, Miki, Kazmierczak, Krystyna, Hackel, Meredith, Sahm, Daniel F, Echols, Roger, Yamano, Yoshinori
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776383/ http://dx.doi.org/10.1093/ofid/ofaa439.1436

Ejemplares similares

In vitro Activity of Cefiderocol Against Gram-Negative Clinical Isolates Collected from Urinary Track Source: SIDERO-WT-2014/SIDERO-WT-2015
por: Tsuji, Masakatsu, et al.
Publicado: (2017)

In Vitro Susceptibility of Gram-Negative Pathogens to Cefiderocol in Five Consecutive Annual Multinational SIDERO-WT Surveillance Studies, 2014 to 2019
por: Karlowsky, James A., et al.
Publicado: (2022)

In Vitro Activity of Cefiderocol Against Meropenem-Nonsusceptible Gram-Negative Bacilli with Defined β-Lactamase Carriage: SIDERO-WT Surveillance Studies, 2014–2019
por: Wise, Mark G., et al.
Publicado: (2023)

696. Cefiderocol Susceptibility Against Molecularly Characterized Carbapenemase-Producing Gram-Negative Bacteria in North America and Europe Between 2014 and 2017: SIDERO-WT-2014 to -2016 Studies
por: Sato, Takafumi, et al.
Publicado: (2019)

1452. Molecular Profile of β-Lactamase Genes and Siderophore-Dependent Iron Transporter Genes of Cefiderocol High MIC Isolates from SIDERO-WT Studies
por: Yamano, Yoshinori, et al.
Publicado: (2020)

1349. Global Surveillance of Cefiderocol Against Gram-Negative Clinical Strains Collected in North America: SIDERO-WT-2015
por: Tsuji, Masakatsu, et al.
Publicado: (2018)

In vitro activity of cefiderocol against MBL-producing Gram-negative bacteria collected in North America and Europe in five consecutive annual multinational SIDERO-WT surveillance studies (2014–2019)
por: Takemura, Miki, et al.
Publicado: (2023)

164. in Vitro Antibacterial Activity of Cefiderocol Against Non-fermenter Clinical Strains Collected in North America and Europe from Multinational Surveillance Studies SIDERO-WT-2014–2018
por: Ukai, Yuuta, et al.
Publicado: (2020)

In vitro Activity of Cefiderocol against Globally Collected Carbapenem-Resistant Gram-Negative Bacteria Isolated from Urinary Track Source: SIDERO-CR-2014/2016
por: Tsuji, Masakatsu, et al.
Publicado: (2017)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study)
por: Hackel, Meredith A., et al.
Publicado: (2017)

692. In Vitro Antibacterial Activity of Cefiderocol Against a Multi-national Collection of Carbapenem-Nonsusceptible Gram-Negative Bacteria From Respiratory Infections: SIDERO-WT-2014–2017
por: Rao, Sonia N, et al.
Publicado: (2019)

679. In vitro Activity of Cefiderocol (CFDC), a Novel Siderophore Cephalosporin, Against Difficult-to-Treat-Resistant (DTR) Gram-Negative Bacterial Pathogens From the Multi-National Sentinel Surveillance Study, SIDERO-WT (2014–2017)
por: Longshaw, Christopher, et al.
Publicado: (2019)

Escherichia coli strains possessing a four amino acid YRIN insertion in PBP3 identified as part of the SIDERO-WT-2014 surveillance study
por: Sato, Takafumi, et al.
Publicado: (2020)

1626. Synergistic Effect of Cefiderocol with Other Antibiotics Against PER-Producing Acinetobacter baumannii Isolates from the Multinational SIDERO-WT Studies
por: Yamano, Yoshinori, et al.
Publicado: (2020)

723. Synergistic Effect of Cefiderocol Combined With Other Antibiotics Against Cefiderocol High MIC Isolates From the Multi-National SIDERO-WT Studies
por: Yamano, Yoshinori, et al.
Publicado: (2019)

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
por: Hackel, Meredith A., et al.
Publicado: (2018)

In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France
por: Naas, Thierry, et al.
Publicado: (2021)

Erratum to: In vitro activity of cefiderocol and comparators against isolates of Gram-negative pathogens from a range of infection sources: SIDERO-WT-2014–2018 studies in France
por: Naas, Thierry, et al.
Publicado: (2021)

1058. In Vitro and In Vivo Antibacterial Activity of Cefiderocol against Burkholderia spp
por: Oota, Merime, et al.
Publicado: (2021)

1066. In Vitro and in Vivo Antimicrobial Activity of Cefiderocol and Comparators against Achromobacter spp
por: Nakai, Ryuichiro, et al.
Publicado: (2021)

Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase–Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies( )
por: Timsit, Jean Francois, et al.
Publicado: (2022)

1455. Potential Mechanisms of Cefiderocol MIC Increase in Enterobacterales in In Vitro Resistance Acquisition Studies
por: Yamano, Yoshinori, et al.
Publicado: (2020)

1715. In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021
por: Yamano, Yoshinori, et al.
Publicado: (2022)

1734. Susceptibility of Cefiderocol between US Census Regions against Gram-Negative Organisms collected from the SENTRY Surveillance Program: 2020-2021
por: Kung, Frank H, et al.
Publicado: (2022)

1269. Differences in Interpretative Breakpoints Between CLSI, FDA and EUCAST Impact Reporting of Susceptibility and Resistance to Cefiderocol
por: Yamano, Yoshinori, et al.
Publicado: (2020)

New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae
por: Nurjadi, Dennis, et al.
Publicado: (2022)

1355. Global Activity of Imipenem–Relebactam and Comparators Against Clinical Gram-Negative Pathogens – SMART 2017
por: Lob, Sibylle, et al.
Publicado: (2018)

Mechanisms of Reduced Susceptibility to Cefiderocol Among Isolates from the CREDIBLE-CR and APEKS-NP Clinical Trials
por: Nordmann, Patrice, et al.
Publicado: (2022)

1256. Clinical Response by Minimum Inhibitory Concentrations in Carbapenem-Resistant Pseudomonas aeruginosa Infections under Cefiderocol Compassionate Use Program
por: Satlin, Michael J, et al.
Publicado: (2021)

1266. Characterization of Shifts in Minimum Inhibitory Concentrations During Treatment with Cefiderocol or Comparators in the Phase 3 CREDIBLE-CR and APEKS-NP Studies
por: Takemura, Miki, et al.
Publicado: (2020)

1252. In Vitro Activity of Aztreonam-Avibactam and Comparator Agents Against Enterobacterales from Patients with Bloodstream Infections collected during the ATLAS Global Surveillance Program, 2015-2019
por: Lob, Sibylle, et al.
Publicado: (2021)

In vitro activity of the siderophore cephalosporin, cefiderocol, against molecularly characterized, carbapenem-non-susceptible Gram-negative bacteria from Europe
por: Longshaw, Christopher, et al.
Publicado: (2020)

In Vitro Activity of Cefiderocol Compared to Other Antimicrobials against a Collection of Metallo-Beta-Lactamase-Producing Gram-Negative Bacilli from Southern Spain
por: Delgado-Valverde, M., et al.
Publicado: (2023)

709. Activity of Key β-Lactam Agents Against Gram-Negative Bacilli From ICU Patients with Lower Respiratory Tract Infections, SMART United States 2015–2017
por: Lob, Sibylle, et al.
Publicado: (2018)

609. In vivo efficacy of human simulated exposures of cefiderocol (FDC) in combination with ceftazidime/avibactam (CZA) or meropenem (MEM) using in a 72 hour murine thigh infection model
por: Gill, Christian M, et al.
Publicado: (2022)

In Vitro Antibacterial Properties of Cefiderocol, a Novel Siderophore Cephalosporin, against Gram-Negative Bacteria
por: Ito, Akinobu, et al.
Publicado: (2017)

In Vitro Activities and Inoculum Effects of Cefiderocol and Aztreonam-Avibactam against Metallo-β-Lactamase-Producing Enterobacteriaceae
por: Huang, Yu-Shan, et al.
Publicado: (2023)

In vivo efficacy & resistance prevention of cefiderocol in combination with ceftazidime/avibactam, ampicillin/sulbactam or meropenem using human-simulated regimens versus Acinetobacter baumannii
por: Gill, Christian M, et al.
Publicado: (2023)

165. Cefiderocol Treatment for Serious Infections Caused by Carbapenem-resistant Bacteria: Post-hoc Analysis of Outcomes by Pathogen in the CREDIBLE-CR Study
por: Matsunaga, Yuko, et al.
Publicado: (2020)

In Vivo Efficacy of Humanized Exposures of Cefiderocol Compared with Cefepime (FEP) and Meropenem (MEM) against Gram-negative Bacteria in a Murine Thigh Model
por: Monogue, Marguerite, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_8sb0p5ge6ihifmcjek9ggg5ut5